Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: A pilot study

Rougier, Sandrine; Vouldoukis, Ioannis; Fournel, Sandrine; Peres, S. Loiseau; Woehrle, Frédérique

doi:10.1016/j.vetpar.2008.01.041

Cited by 20 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…D'autre part, le traitement doit empêcher la contagiosité des animaux infectés. La prescription d'un antiparasitaire externe, obligatoirement à base de pyréthrinoïdes (deltaméthrine ou association imidaclopride/perméthrine) permet d'avoir un effet « knock down » sur les phlébotomes [32][33][34]. Enfin, il ne faut pas oublier que ce traitement antiparasitaire reste le meilleur moyen de prévention de la maladie chez les animaux sains [24,32,33].…”

Section: Discussionunclassified

“…Il semblerait ensuite que l'administration d'une fluoroquinolone en première intention, lors de la prise en charge du chien, puisse contribuer à l'amélioration clinique. En effet, une étude récente montre que ces antibiotiques auraient un effet immunomodulateur en diminuant la production de cytokines [34]. Leur effet leishmanicide reste cependant à confirmer, la mesure d'efficacité étant, dans cette étude pilote, l'intensité de l'infestation des macrophages.…”

Section: Discussionunclassified

See 1 more Smart Citation

Polyarthrite associée à une leishmaniose chez un jeune chien

Collignon¹,

Zahra²,

Guénégo³

et al. 2009

Pratique Médicale et Chirurgicale de l'Animal de Compagnie

View full text Add to dashboard Cite

Section: Discussionunclassified

Polyarthrite associée à une leishmaniose chez un jeune chien

Collignon¹,

Zahra²,

Guénégo³

et al. 2009

Pratique Médicale et Chirurgicale de l'Animal de Compagnie

View full text Add to dashboard Cite

“…Studies supporting the in vitro and in vivo efficacy of marbofloxacin against Leishmania have been published by Vouldoukis et al (2006) and Rougier et al (2008). Marbofloxacin shows direct and indirect leishmanicidal activity with the latest being the most relevant.…”

Section: Discussionmentioning

confidence: 99%

Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

et al. 2012

View full text Add to dashboard Cite

Despite the availability of different therapeutic options, canine visceral leishmaniosis (CVL) remains a challenging disease to treat. Recently miltefosine has been registered for use in dogs, and different studies have demonstrated its leishmanicidal effect. Moreover, it has been suggested that fluoroquinolones, compared to standard chemotherapeutic agents, could be an effective and pragmatic alternative to treat CVL. The efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum was assessed in vitro by incubating increasing concentrations of the drugs with a standard parasite inoculum. Miltefosine was significantly more efficacious than marbofloxacin (P < 0.05) against the two strains of L. infantum either alone or in combination with allopurinol. Both drugs were significantly (P < 0.05) more efficacious when associated with allopurinol than alone.

show abstract

“…Miltefosine was more efficacious than marbofloxacin, but when compared to meglumine antimoniate and sodium stibogluconate, marbofloxacin was more efficacious, with increases in NO and TNF-α observed after marbofloxacin treatment (135). Dogs naturally infected with visceral leishmaniasis and treated daily with a dose of 2 mg/kg marbofloxacin for different period of times, and the treatment for 28 days lead to clinical improvement and was considered, safe and efficient (136).…”

Section: Antibioticsmentioning

confidence: 99%

Leishmaniasis treatment update of possibilities for drug repurposing

Torres-Santos¹

2018

Front Biosci

View full text Add to dashboard Cite

The leishmaniases represent a public health problem in under-developed countries and are considered a neglected disease by the World Health Organization (WHO). They are cuased by parasites with different clinical manifestations. Currently, there is no vaccine, and treatment is in-efficient and is associated with both serious side effects often leading to resistance to the parasites. Thus, it is essential to search for new treatment strategies, such as drug repurposing, i.e., the use of drugs that are already used for other diseases. The discovery of new clinical applications for approved drugs is strategic for lowering the cost of drug discovery since human toxicity assays are already conducted. Here, we review a broad analysis of the different aspects of this approach for anti-leishmanial treatment.

show abstract

Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: A pilot study

Cited by 20 publications

References 30 publications

Polyarthrite associée à une leishmaniose chez un jeune chien

Polyarthrite associée à une leishmaniose chez un jeune chien

Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum

Leishmaniasis treatment update of possibilities for drug repurposing

Contact Info

Product

Resources

About